Importantly, the promoter methylation status of the DNA repairing enzyme methylguanine-DNA methyltransferase (MGMT) is considered a predictive marker for the response of patients with GBM to TMZ therapy [52]. The gene discussed is MGMT; the disease is glioblastoma.